2083. Induction-concurrent chemoradiotherapy with or without sintilimab in patients with locoregionally advanced nasopharyngeal carcinoma in China (CONTINUUM): a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial.
作者: Xu Liu.;Yuan Zhang.;Kun-Yu Yang.;Ning Zhang.;Feng Jin.;Guo-Rong Zou.;Xiao-Dong Zhu.;Fang-Yun Xie.;Xiao-Yu Liang.;Wen-Fei Li.;Zhen-Yu He.;Nian-Yong Chen.;Wei-Han Hu.;Hai-Jun Wu.;Mei Shi.;Guan-Qun Zhou.;Yan-Ping Mao.;Rui Guo.;Rui Sun.;Jing Huang.;Shao-Qiang Liang.;Wei-Li Wu.;Zhen Su.;Ling Li.;Ping Ai.;Yu-Xiang He.;Jian Zang.;Lei Chen.;Li Lin.;Shao Hui Huang.;Cheng Xu.;Jia-Wei Lv.;Ying-Qing Li.;Shu-Bin Hong.;Yu-Sheng Jie.;Hao Li.;Sai-Wei Huang.;Ye-Lin Liang.;Ya-Qin Wang.;Ying-Lin Peng.;Jin-Han Zhu.;Sheng-Bing Zang.;Song-Ran Liu.;Qing-Guang Lin.;Hao-Jiang Li.;Li Tian.;Li-Zhi Liu.;Hong-Yun Zhao.;Ai-Hua Lin.;Ji-Bin Li.;Na Liu.;Ling-Long Tang.;Yu-Pei Chen.;Ying Sun.;Jun Ma.
来源: Lancet. 2024年403卷10445期2720-2731页
Anti-PD-1 therapy and chemotherapy is a recommended first-line treatment for recurrent or metastatic nasopharyngeal carcinoma, but the role of PD-1 blockade remains unknown in patients with locoregionally advanced nasopharyngeal carcinoma. We assessed the addition of sintilimab, a PD-1 inhibitor, to standard chemoradiotherapy in this patient population.
2090. Opioids for back and neck pain: the OPAL trial - Authors' reply.
作者: Caitlin M P Jones.;Richard O Day.;Bart W Koes.;Jane Latimer.;Chris G Maher.;Andrew J McLachlan.;Laurent Billot.;Sana Shan.;Chung-Wei Christine Lin.; .
来源: Lancet. 2024年403卷10442期2379-2380页 |